Wolfe Research Begins Coverage on Incyte (NASDAQ:INCY)

Wolfe Research initiated coverage on shares of Incyte (NASDAQ:INCY – Free Report) in a research report released on Tuesday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $84.00 target price on the biopharmaceutical company’s stock. A number of other research firms also recently issued reports on INCY. Truist Financial reaffirmed a […]

Leave a Reply

Your email address will not be published.

Previous post Hologic (NASDAQ:HOLX) Cut to “Neutral” at Citigroup
Next post Morgan Stanley Trims Lululemon Athletica (NASDAQ:LULU) Target Price to $314.00